Increased central systolic loading may contribute to ischaemic symptoms in cardiac syndrome X (CSX). Resting and exercise-induced central pressure waveforms were recorded in 20 CSX patients and 20 controls. Patients with CSX had significantly higher wave reflection and reduced pulse pressure amplification, which may help to explain symptoms in CSX.
The cardiac syndrome X (CSX) condition seriously impairs quality of life and is costly to the health-care system. 1 Although the aetiology is probably multifactorial, there is evidence to implicate coronary microvascular dysfunction (leading to myocardial underperfusion) as playing a major role. 2 However, studies have shown impaired brachial artery vasodilation 3, 4 and microcirculatory derangement at multiple vascular beds in CSX patients, 5 implying that arterial irregularities may be a systemic phenomenon. This may adversely affect cardiac function through increased arterial wave reflections.
Due to individual variance between central and brachial systolic blood pressure, high central systolic blood pressure and pulse pressure (PP) may not be detectable by traditional cuff blood pressure (BP) measures. New technology allows non-invasive assessment of central BP by radial tonometry and pulse wave analysis. 6 Using this methodology, we recently reported the case of a CSX patient whose abnormal pulse waveforms were improved and symptoms resolved after treatment. 7 Following on from this observation, we sought to test the hypothesis that abnormal arterial pressure waveforms and exercise haemodynamics may be a common finding, potentially contributing to ischaemia, in CSX.
Twenty patients with CSX were identified from hospital records. Only those with a history of angina, a positive electrocardiographic exercise stress test and angiographically normal coronary arteries (o50% stenosis) were recruited. Patients taking calcium channel blockers and those with a history of cardiomyopathy or valvular heart disease were excluded. Healthy controls (n ¼ 20) matched by age, gender, height and mean arterial pressure (MAP) were recruited from the community. None of the controls had a history of coronary artery disease and all had normal stress echocardiograms. None of the study participants had known or suspected left ventricular dysfunction. Subjects were assessed at rest and immediately after a maximal treadmill test to volitional fatigue. The b-blocker medication was withheld on the day of testing.
Supine resting BP was the average of two readings (after X10 min rest) by cuff sphygmomanometry. Exercise BP was recorded during the final minute of maximal exertion. Central (ascending aorta) pressure waveforms were synthesized from the radial pulse by applanation tonometry (SphygmoCor 7.01; AtCor Medical, Sydney, Australia) at rest and immediately after exercise (supine) using an exercise-validated algorithm. 8 Augmentation index (AIx; a measure of wave reflection) was defined as central augmented pressure as a percentage of central PP, and was also corrected to 75 b.p.m. using SphygmoCor software. PP amplification was calculated as the ratio of peripheral to central PP (analysis of covariance was used to adjust for heart rate when comparing resting AIx and PP amplification between groups). Resting aortic and brachial artery stiffness was determined by pulse wave velocity (SphygmoCor 7.01).
There were no significant differences between the groups in age (mean7s.d.; CSX; 61711 versus 5879 years; P ¼ 0.46), gender (12 females in each), height (CSX; 1.6570.09 versus 1.6870.10 m; P ¼ 0.32), weight (CSX; 74713 versus 74711 kg; P ¼ 0.94), creatinine clearance (CSX; 88728 versus 90718 ml min ; P ¼ 0.26; all blood biochemistry taken from patient records) or the number of smokers (current, former or never smoked, CSX; 1/10/9 versus 1/7/12 respectively; P40.05).
At rest, there were no significant differences in MAP, brachial or central BP ( ; P ¼ 0.77) pulse wave velocity. However, CSX patients had significantly higher AIx and reduced PP amplification. Although heart rate was significantly lower in CSX patients, ejection duration was similar between groups (CSX; 335724 versus 326720 ms; P ¼ 0.22). The AIx corrected to 75 b.p.m. was not significantly different between groups (CSX; 2578 versus 22712%; P ¼ 0.35). As expected, AIx was significantly correlated with height (r ¼ À0.55; Po0.05) and MAP (r ¼ 0.64; Po0.01) in controls. However, no such relationships were observed in CSX patients (r ¼ À0.23; P ¼ 0.36 and r ¼ 0.26; P ¼ 0.27, respectively).
With exercise, CSX patients had significantly higher brachial (CSX; 91714 versus 80711 mm Hg; P ¼ 0.01) and central (CSX; 95714 versus 86712 mm Hg; P ¼ 0.04) diastolic BP, peripheral (CSX; 109712 versus 96713 mm Hg; P ¼ 0.004) and central (CSX; 134712 versus 125712 mm Hg; P ¼ 0.03) end systolic pressure. For all participants, central end systolic pressure during exercise was significantly correlated to resting aortic pulse wave velocity (r ¼ 0.42) and AIx (r ¼ 0.35; Po0.05 for both).
Patients with CSX had significantly higher use of statins (n ¼ 6 versus n ¼ 0) and antiplatelet agents (n ¼ 6 versus n ¼ 0; Po0.05 for both), accounting for 10 patients in total. When these patients were excluded from analysis, PP amplification remained significantly lower than controls (1.2270.09 versus 1.3470.13; P ¼ 0.03) and AIx was higher (3179 versus 24710%), but of borderline significance (P ¼ 0.05). Although not significant, CSX patients had increased use of angiotensin converting enzyme inhibitors (n ¼ 3 versus n ¼ 1; P ¼ 0.60), b-blockers (n ¼ 5 versus n ¼ 0; P ¼ 0.06) and diuretics (n ¼ 1 versus n ¼ 0; P ¼ 1.0). The 5 CSX patients on b-blockers had a resting heart rate of 6179 b.p.m., which was not significantly different from the remaining 15 CSX patients (63710 b.p.m.; P ¼ 0.72) and there were no significant differences between these patients for AIx (5 patients, 3276 versus remainder 3179%; P ¼ 0.71) or PP amplification (5 patients, 1.2370.06 versus remainder 1.2370.11; P ¼ 0.95). Similarly, there was no significant difference between statin and non-statin patients for AIx (statin 3575 versus non-statin 2979%; P ¼ 0.12) and PP amplification (statin 1.1870.06 versus non-statin 1.2570.10; P ¼ 0.10).
The novel findings of this study were that patients with CSX had increased wave reflection and high central relative to brachial PP at rest. Furthermore, end systolic pressure and diastolic BP (centrally and peripherally) were significantly elevated in CSX patients after exercise. This is an observational study with a rather small sample size that cannot attribute cause and effect. However, our data indicate that CSX patients may have central haemodynamic irregularities of possible clinical importance. Indeed, increased AIx may play a contributory role in myocardial ischaemia by generating an unfavourable balance between left ventricular metabolic demand and supply, thus depleting the time and pressure available for coronary microvasculature perfusion.
There are several possible reasons for the enhanced AIx in CSX because the timing and amplitude of reflected pressure waves are influenced by numerous factors including age, gender, height, MAP, heart rate and arterial stiffness. 9 With the exception of heart rate, none of these variables significantly differed between groups. This study cannot discern whether bradycardia is intrinsic to the CSX condition; however, this is recognized as being detrimental to cardiac function 10 and, to our knowledge, has not previously been reported in CSX patients. Importantly, our data do not suggest that bblocker drugs skewed our findings; however, we cannot rule out other medications such as statins and/or antiplatelet agents as possible confounders.
The lower heart rate in CSX patients is unlikely to entirely account for the AIx increase because (1) ejection duration was similar between groups, (2) significant differences in AIx remained between groups after statistical correction for heart rate and (3) the heart rate difference between groups (8 b.p.m.) would only account for about 3% AIx, 11 whereas the actual difference was a statistically significant 7%. Moreover, MAP and height are well known to correlate with AIx, but these associations were only demonstrated in the controls and not the CSX patients. A possible cause of higher wave reflection is increased vascular resistance at the arteriolar level since this is thought to be the major site of wave reflection. Overall, the findings suggest that pulse wave analysis may be useful for guiding therapy in CSX patients.
